甘精胰岛素对2型糖尿病患者体内丙二醛水平的影响

Effect of glargine on malondialdehyde in type 2 diabetic patients

目的:糖尿病患者长期高血糖引起体内氧化产物增加,直接导致糖尿病并发症的发生,文中通过检测应用甘精胰岛素治疗的2型糖尿病患者血中丙二醛(MDA)水平变化,探讨2型糖尿病治疗前后体内氧化应激水平的变化及影响因素。方法:选取32例2型糖尿病患者,比较其治疗前后空腹血糖(FBG)、餐后血糖(PBG)、三酰甘油(TG)、糖化血红蛋白(HbA lc)、MDA等相关指标,同时选择性别年龄相匹配的健康体检者26名作为对照,分析这些指标在治疗前后的变化。结果:32例患者治疗前后的TG、FBG、PBG、HbA lc差异有统计学意义(P<0.05),治疗后血MDA水平较治疗前明显下降(P<0.01),较健康正常人比较,MDA水平仍较高,(P<0.01);Pearson相关性分析显示MDA与FBG、PBG、HbA1 c、胰岛素用量呈正相关(r=0.443,P=0.011;r=0.411,P=0.001;r=0.391,P=0.027;r=0.405,P=0.021)。结论:应用甘精胰岛素治疗2型糖尿病,在降低血糖、血脂的同时,可以减轻2型糖尿病患者体内的氧化应激水平,后者与血糖水平及胰岛素用量相关。

Objective： Diabetes with hyperglycemia can produce more oxidative products which associated with diabetic complication.In this article we explore the effect of glargine in the developing of chronic complications of type 2 diabetes through detecting the Malondialdehyde level in type 2 diabetic patients with glargine therapy.Methods： 32 diabetic patients whose blood glucose was not controlled in ideal level were added glargine insulin treatment.26 healthy persons were selected to match the sex and age of diabetes patients.Fasting blood glucose（FPG）,postprandial blood glucose（PBG）,triglyceride（TG）,glycosylated hemoglobin（HbAlc）,human Malondialdehyde（MDA） were detected,and compared variance of these markers between before glargine treatment and after glargine treatment.Results： There were significant differences in TG,FPG,PBG and HbAlc before and after treatment（P〈0.05）.The level of MDA in diabetes mellitus group was significantly decreased after glargine treatment（P〈0.01）,but higher than that in healthy persons（P〈0.01）.The correlation analysis showed that MDA was positively correlated with FBG,PBG,HbAlc and insulin dose（r=0.443,P=0.011;r=0.411,P=0.001;r=0.391,P=0.027;r=0.405,P=0.021）.Conclusion： Patients with type 2 diabetes using insulin glargine could have ideal blood glucose level and decreased oxidative stress.The latter appears to be closely associated with blood sugar level and insulin dose,and it may play an important role on delaying the development of chronic complications of type 2 diabetes.